Quality Street: India Needs A Frances Kelsey, Many Of Her Kind
Scrip delves into some of India’s critical compliance and quality challenges and efforts to address those.
You may also be interested in...
Could more Indian firms consider re-aligning their US business amid heightened pricing and compliance pressures that have cast a shadow on the long-term viability of the generics segment? A cross section of experts including a senior executive at McKinsey & Co share their views on what to expect.
FDA officials highlight at a recent summit in India recurring issues around drug manufacturing compliance including microbial contamination and data integrity concerns but emphasize that the agency isn’t in a “gotcha” mode for companies.
As politicians demand help for cancer-ridden constituents, the agency allows Indian plant that flunked inspection to resume exporting batches of cisplatin and carboplatin to the US, but only after passing independent 45-day batch certification reviews.